Cargando…
Should We Use Dialyzable β-Blockers in Hemodialysis?
Autores principales: | Georgianos, Panagiotis I., Eleftheriadis, Theodoros, Liakopoulos, Vassilios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079235/ https://www.ncbi.nlm.nih.gov/pubmed/35539429 http://dx.doi.org/10.1016/j.xkme.2022.100468 |
Ejemplares similares
-
Therapeutic Advances in Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2023) -
Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022) -
Hypertension in Dialysis Patients: Diagnostic Approaches and Evaluation of Epidemiology
por: Georgianos, Panagiotis I., et al.
Publicado: (2022) -
Eating during the Hemodialysis Session: A Practice Improving Nutritional Status or a Risk Factor for Intradialytic Hypotension and Reduced Dialysis Adequacy?
por: Fotiadou, Eleni, et al.
Publicado: (2020) -
Oxidized LDL Modifies the Association between Proteinuria and Deterioration of Kidney Function in Proteinuric Diabetic Kidney Disease
por: Roumeliotis, Stefanos, et al.
Publicado: (2021)